Several investigations have demonstrated that RIG‐I agonists greatly induce synergistic anti‐tumour effects when combined with immune checkpoint inhibitors, such as anti‐CTLA‐4 and anti‐PD‐1 antibodies (Heidegger et al., 2019; Jiang et al., 2019; Ruzicka et al., 2020). This evidence concerns the gene CTLA4 and neoplasm.